HERO Study TE: Discussion Videos

Journal Club: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer - Zachary Klaassen Details Christopher Wallis and Zachary Klaassen host this journal club on "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer," published by the HERO trial investigators in the New England Journal of Medicine simultaneously with the first presentation of the trial results at the ASCO 2020 annual meeting. Sharing background information on androgen deprivation therapy (ADT), as well...
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore Details Relugolix is the first oral GnRH receptor antagonist, which was previously shown to rapidly suppress testosterone levels. Neal Shore joins Alicia Morgans to discuss the results of the HERO phase 3 trial comparing the safety and efficacy of relugolix with leuprolide acetate in advanced prostate cancer patients. Relugolix is an oral, once a day medication, and the trial had a primary endpoint of non...

Journal Club: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer - Zachary Klaassen